ATE303998T1 - Oral aktive salze mit tyrosinkinaseaktivität - Google Patents
Oral aktive salze mit tyrosinkinaseaktivitätInfo
- Publication number
- ATE303998T1 ATE303998T1 AT01987742T AT01987742T ATE303998T1 AT E303998 T1 ATE303998 T1 AT E303998T1 AT 01987742 T AT01987742 T AT 01987742T AT 01987742 T AT01987742 T AT 01987742T AT E303998 T1 ATE303998 T1 AT E303998T1
- Authority
- AT
- Austria
- Prior art keywords
- tyrosine kinase
- active salts
- kinase activity
- oral active
- compounds
- Prior art date
Links
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title abstract 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24104300P | 2000-10-17 | 2000-10-17 | |
| PCT/US2001/032508 WO2002032861A2 (en) | 2000-10-17 | 2001-10-17 | Orally active salts with tyrosine kinase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE303998T1 true ATE303998T1 (de) | 2005-09-15 |
Family
ID=22909009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01987742T ATE303998T1 (de) | 2000-10-17 | 2001-10-17 | Oral aktive salze mit tyrosinkinaseaktivität |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6960590B2 (de) |
| EP (1) | EP1328519B1 (de) |
| JP (1) | JP2004511541A (de) |
| AT (1) | ATE303998T1 (de) |
| AU (2) | AU2687702A (de) |
| CA (1) | CA2424689A1 (de) |
| DE (1) | DE60113286T2 (de) |
| ES (1) | ES2247187T3 (de) |
| WO (1) | WO2002032861A2 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4341949B2 (ja) | 2000-09-01 | 2009-10-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アザ複素環式誘導体およびその治療的使用 |
| PL211125B1 (pl) | 2000-09-11 | 2012-04-30 | Novartis Vaccines & Diagnostic | Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie |
| AU2687702A (en) * | 2000-10-17 | 2002-04-29 | Merck & Co Inc | Orally active salts with tyrosine kinase activity |
| WO2003020276A1 (en) * | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2480325A1 (en) * | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Solid forms of salts with tyrosine kinase activity |
| ATE360015T1 (de) * | 2002-07-31 | 2007-05-15 | Critical Outcome Technologies | Protein tyrosin kinase inhibitoren |
| KR20050037585A (ko) | 2002-08-23 | 2005-04-22 | 카이론 코포레이션 | 벤지미다졸 퀴놀리논 및 그들의 사용 |
| ATE380810T1 (de) * | 2002-10-09 | 2007-12-15 | Critical Outcome Technologies | Protein-tyrosine-kinase-inhibitoren |
| AR043880A1 (es) * | 2003-04-22 | 2005-08-17 | Solvay Pharm Gmbh | Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas |
| AU2004251175A1 (en) * | 2003-06-05 | 2005-01-06 | Merck & Co., Inc. | Substituted indoles and a process for preparing substituted indoles |
| TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| EP2465857B1 (de) | 2005-05-17 | 2014-06-04 | Novartis AG | Verfahren zum Synthetisieren heterocyclischer Verbindungen |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| CN101340909B (zh) | 2005-10-18 | 2012-01-11 | 詹森药业有限公司 | 抑制flt3激酶的方法 |
| US8658633B2 (en) * | 2006-02-16 | 2014-02-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| EP2016070B1 (de) | 2006-04-20 | 2016-01-13 | Janssen Pharmaceutica N.V. | Inhibitoren von c-fms-kinase |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| US7414050B2 (en) | 2006-04-20 | 2008-08-19 | Janssen Pharmaceutica, N.V. | Inhibitors of c-fms kinase |
| ES2427924T3 (es) | 2006-06-30 | 2013-11-04 | Merck Sharp & Dohme Corp. | Biomarcador IGFBP2 |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| EP2121681B1 (de) | 2007-01-11 | 2015-04-15 | Critical Outcome Technologies, Inc. | Verbindungen und verfahren zur behandlung von krebs |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| MX2010004327A (es) | 2007-10-22 | 2010-05-13 | Schering Corp | Anticuerpos anti-vegf completamente humanos y metodos de uso. |
| WO2009079797A1 (en) * | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| EP3023426A1 (de) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren |
| CA2756870A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| EP2521782B1 (de) | 2010-01-05 | 2019-04-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | FLT3-Rezeptorantagonisten zur Behandlung oder Vorbeugung von Schmerzstörungen |
| AU2011206621B2 (en) | 2010-01-12 | 2016-04-14 | Ab Science | Thiazole and oxazole kinase inhibitors |
| WO2011120153A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| US9303046B2 (en) | 2012-08-07 | 2016-04-05 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
| KR101738063B1 (ko) | 2012-09-21 | 2017-05-19 | 아로그 파마슈티칼스, 인코퍼레이티드 | 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법 |
| BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
| FR3008411B1 (fr) * | 2013-07-12 | 2015-07-03 | Servier Lab | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| AU2015295288B2 (en) | 2014-07-31 | 2019-10-31 | Centre National De La Recherche Scientifique (Cnrs) | FLT3 receptor antagonists |
| EP3254698A1 (de) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3-rezeptor-inhibitoren bei niedriger dosierung zur behandlung von neuropathischem schmerz |
| ES3014630T3 (en) | 2016-07-29 | 2025-04-23 | Janssen Pharmaceutica Nv | Niraparib for use in a method of treating prostate cancer |
| US10305868B2 (en) * | 2016-09-30 | 2019-05-28 | Uchicago Argonne, Llc | Stream splitting moving target defense |
| EP3359155A4 (de) | 2016-11-02 | 2019-05-22 | Arog Pharmaceuticals, Inc. | Crenolanib zur behandlung von mutationen im zusammenhang mit flt3-mutierten proliferativen erkrankungen |
| KR20200013683A (ko) | 2017-05-17 | 2020-02-07 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 오피오이드에 의한 통증 치료 개선용 ｆｌｔ3 저해제 |
| WO2019057649A1 (en) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| WO2022090547A1 (en) | 2020-10-30 | 2022-05-05 | Dsm Ip Assets B.V. | Production of carotenoids by fermentation |
| US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0584222B1 (de) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| US5578609A (en) | 1994-03-25 | 1996-11-26 | The Dupont Merck Pharmaceutical Company | 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents |
| GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| EP0918522A4 (de) | 1996-05-20 | 1999-08-18 | Merck & Co Inc | Antagonisten des gonadotropin-releasinghormons |
| IL129825A0 (en) | 1996-11-27 | 2000-02-29 | Pfizer | Fused bicyclic pyrimidine derivatives |
| JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
| EP1226136B1 (de) * | 1999-10-19 | 2004-12-29 | Merck & Co., Inc. | Tyrosin kinaseinhibitoren |
| AU2687702A (en) * | 2000-10-17 | 2002-04-29 | Merck & Co Inc | Orally active salts with tyrosine kinase activity |
-
2001
- 2001-10-17 AU AU2687702A patent/AU2687702A/xx active Pending
- 2001-10-17 CA CA002424689A patent/CA2424689A1/en not_active Abandoned
- 2001-10-17 JP JP2002536045A patent/JP2004511541A/ja active Pending
- 2001-10-17 ES ES01987742T patent/ES2247187T3/es not_active Expired - Lifetime
- 2001-10-17 DE DE60113286T patent/DE60113286T2/de not_active Expired - Fee Related
- 2001-10-17 WO PCT/US2001/032508 patent/WO2002032861A2/en not_active Ceased
- 2001-10-17 EP EP01987742A patent/EP1328519B1/de not_active Expired - Lifetime
- 2001-10-17 AT AT01987742T patent/ATE303998T1/de not_active IP Right Cessation
- 2001-10-17 US US10/398,851 patent/US6960590B2/en not_active Expired - Fee Related
- 2001-10-17 AU AU2002226877A patent/AU2002226877B2/en not_active Ceased
- 2001-10-17 US US09/981,979 patent/US6656942B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2247187T3 (es) | 2006-03-01 |
| EP1328519A2 (de) | 2003-07-23 |
| US20020072526A1 (en) | 2002-06-13 |
| AU2002226877B2 (en) | 2006-01-12 |
| DE60113286D1 (de) | 2005-10-13 |
| EP1328519A4 (de) | 2004-12-15 |
| US20040002501A1 (en) | 2004-01-01 |
| US6960590B2 (en) | 2005-11-01 |
| WO2002032861A2 (en) | 2002-04-25 |
| JP2004511541A (ja) | 2004-04-15 |
| AU2687702A (en) | 2002-04-29 |
| WO2002032861A3 (en) | 2002-08-15 |
| CA2424689A1 (en) | 2002-04-25 |
| US6656942B2 (en) | 2003-12-02 |
| DE60113286T2 (de) | 2006-06-22 |
| EP1328519B1 (de) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60113286D1 (de) | Oral aktive salze mit tyrosinkinaseaktivität | |
| NO20021166D0 (no) | Tyrosinkinase-inhibitorer | |
| EP1226119A4 (de) | Tyrosin kinase inhibitoren | |
| ATE368457T1 (de) | Tyrosinkinase inhibitoren | |
| EP1503757A4 (de) | Tyrosinkinase-hemmer | |
| DE60208792D1 (de) | Tyrosin-kinase inhibitoren | |
| WO2003088900A3 (en) | Solid forms of salts with tyrosine kinase activity | |
| YU28602A (sh) | Inhibitori tirozin kinaze | |
| WO2002045652A3 (en) | Tyrosine kinase inhibitors | |
| WO2003037252A3 (en) | Tyrosine kinase inhibitors | |
| WO2004052315A3 (en) | Tyrosine kinase inhibitors | |
| WO2004041164A3 (en) | Kinase inhibitors | |
| MXPA04004492A (es) | Indazolilpirrolotriazinas c-5 modificadas. | |
| NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
| EA200700220A1 (ru) | Имидазотриазины в качестве ингибиторов протеинкиназы | |
| LU92508I2 (fr) | Cabozantinib et toutes les formes thérapeutiquement équivalentes qui en dérivent telles que protégées par le brevet de base, y compris les sels pharmacetuiquement acceptables | |
| DE60234278D1 (de) | Mitotische kinesin-hemmer | |
| WO2003020699A3 (en) | Tyrosine kinase inhibitors | |
| DE602005023732D1 (de) | Pyrrolotriazinverbindungen | |
| WO2003015717A3 (en) | Tyrosine kinase inhibitors | |
| ECSP003729A (es) | Inhibidores de la tirosina quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |